Skip to main content

Table 1 Patient characteristics

From: Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia

Median age (years) 69,9 [58.6–78.3]
D’Amico risk stratification
 Low risk 13 (21%)
 Intermediate risk 23 (37%)
 High risk 26 (42%)
Median pre-treatment PSA level 13.7 ng/mL [1.5–94]
Gleason score
 6 22 (35.5%)
 7 (3 + 4) 18 (29%)
 7 (4 + 3) 9 (14.5%)
  ≥ 8 13 (21%)
T Stage
 T1a/b 5 (8%)
 T1c 27 (43.5%)
 T2 20 (32.5%)
 T3a 5 (8%)
 T3b 5 (8%)
N Stage
 N0 60 (96.7%)
 N1 2 (3.3%)
Prostate surgery
 TURP 52 (84%)
 Vaporization 2 (3%)
 Adenectomy 8 (13%)
Androgen deprivation therapy 30 (48.5%)
Diabete mellitus (n = 61) 11 (18%)
Arterial hypertension (n = 61) 33 (54%)
Medical treatmenta 7 (11.3%)
Prostatic volume before surgery (n = 59) 59.5 cc [3–150]
Prostatic volume after surgery (n = 54) 26.8 cc [3–100]
Median RT dose 78.5 Gy [70–80]
 70 Gy 3 (4.9%)
 76 Gy 15 (24.2%)
 80 Gy 44 (70.9%)
Whole-pelvis RT 6 (9.6%)
Bladder volume receiving 70 Gy (n = 57) 34.7 cc [1–86]
  1. RT Radiotherapy, TURP (Trans-urethral resection of prostate)
  2. a alpha blocker or anticholinergic (solifenacin succinate)